Genotypic and phenotypic features of de novo and acquired resistance to cancer therapies.

被引：0
|
作者：
Dancey, Janet E. [1 ]
机构：
[1] Ontario Inst Canc Res, Toronto, ON, Canada
来源：
CANCER RESEARCH | 2013年 / 73卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2013-SY03-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SY0301
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Role of HGF-MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer
    Della Corte, Carminia Maria
    Fasano, Morena
    Papaccio, Federica
    Ciardiello, Fortunato
    Morgillo, Floriana
    BIOMEDICINES, 2014, 2 (04): : 345 - 358
  • [42] Molecular and Clinical Determinants of Acquired Resistance and Treatment Duration for Targeted Therapies in Colorectal Cancer
    Harrold, Emily
    Keane, Fergus
    Walch, Henry
    Chou, Joanne F.
    Sinopoli, Jenna
    Palladino, Silvia
    Al-Rawi, Duaa H.
    Chadalavada, Kalyani
    Manca, Paolo
    Chalasani, Sree
    Yang, Jessica
    Cercek, Andrea
    Shia, Jinru
    Capanu, Marinela
    Bakhoum, Samuel F.
    Schultz, Nikolaus
    Chatila, Walid K.
    Yaeger, Rona
    CLINICAL CANCER RESEARCH, 2024, 30 (12) : 2672 - 2683
  • [43] Response and acquired resistance to MET inhibitors in de novo MET fusion-positive advanced non-small cell lung cancer
    Kang, Jin
    Deng, Qiu-Mei
    Feng, Weineng
    Chen, Zi-Hao
    Su, Jun-Wei
    Chen, Hua-Jun
    Wang, Wen-xian
    Zhang, Shirong
    Wang, Qian
    Chen, Zexin
    Zhong, Wen-Zhao
    Xu, Chun-wei
    Yang, Jin-Ji
    LUNG CANCER, 2023, 178 : 66 - 74
  • [44] Acquired resistance to osimertinib in patients with de novo EGFRT790M-positive non-small cell lung cancer (NSCLC)
    Park, Ha-Ram
    Lee, Yusoo
    Kim, Tae Min
    Kim, Soyeon
    Ock, Chan-Young
    Kim, Miso
    Keam, Bhumsuk
    Jeon, Yoon Kyung
    Kim, Dong-Wan
    Heo, Dae Seog
    CANCER RESEARCH, 2019, 79 (13)
  • [45] MET amplification in metastatic colorectal cancer: An acquired response to EGFR inhibition, not a de novo phenomenon
    Raghav, Kanwal
    Morris, Van
    Tang, Chad
    Morelli, Pia
    Amin, Hesham M.
    Chen, Ken
    Manyam, Ganiraju C.
    Broom, Bradley
    Overman, Michael J.
    Shaw, Kenna
    Meric-Bernstam, Funda
    Maru, Dipen
    Menter, David
    Ellis, Lee M.
    Eng, Cathy
    Hong, David
    Kopetz, Scott
    ONCOTARGET, 2016, 7 (34) : 54627 - 54631
  • [46] Glucuronidation as a de novo mechanism of drug resistance in colon cancer cells.
    Cummings, J
    Boyd, G
    Ethell, BT
    Macpherson, JS
    Burchell, B
    Smyth, JF
    Jodrell, DI
    CLINICAL CANCER RESEARCH, 2000, 6 : 4505S - 4505S
  • [47] In vitro and in vivo phenotypic and genotypic characterizations of breast, liver, and renal cancer models mimicking human resistance to sunitinib
    Bousquet, Guilhem
    Varna, Mariana
    El Bouchtaoui, Morad
    Sablin, Marie-paule
    Bieche, Ivan
    Ferreira, Irmine
    Serova, Maria
    Faivre, Sandrine
    Astorgues-Xerri, Lucile
    Raymond, Eric
    Janin, Anne
    CANCER RESEARCH, 2009, 69
  • [48] Overcoming de novo and acquired modes of cetuximab resistance by broad-spectrum receptor tyrosine kinase inhibitors
    Singh, Bhuminder
    Graves-Deal, Ramona
    Bogatcheva, Galina
    Coffey, Robert J.
    CANCER RESEARCH, 2019, 79 (13)
  • [49] Cell adhesion is a key determinant in de novo multidrug resistance (MDR):: New targets for the prevention of acquired MDR
    Shain, KH
    Dalton, WS
    MOLECULAR CANCER THERAPEUTICS, 2001, 1 (01) : 69 - 78
  • [50] De Novo Genotypic Heterogeneity in the UL56 Region in Cytomegalovirus-Infected Tissues: Implications for Primary Letermovir Resistance
    Jo, Horim
    Kwon, Da Eun
    Han, Sang Hoon
    Min, Seo Yeon
    Hong, Yeon-Mi
    Lim, Beom Jin
    Lee, Kyoung Hwa
    Jo, Jeong-Hyeon
    JOURNAL OF INFECTIOUS DISEASES, 2020, 221 (09): : 1480 - 1487
12345